Document 1121
 DOCN  M94A1121
 TI    Didanosine (ddI)-induced fulminant hepatitis.
 DT    9412
 AU    Bissuel F; Cotte L; Bruneel F; Lucet J; Trepo C; Hotel-Dieu Hospital,
       Lyon, France.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):204 (abstract no. PB0831). Unique
       Identifier : AIDSLINE ICA10/94371454
 AB    OBJECTIVE: We report 2 cases of fulminant hepatic failure in
       HIV-1-infected patients treated with ddI. METHODS: We retrospectively
       compared the clinical, biological and histological features in the two
       cases. Neither of the 2 patients had any prior history of liver disease.
       RESULTS: Clinical manifestations were identical and outcome was fatal in
       both patients despite resuscitation measures. No superimposed infectious
       cause could be found, including hepatitis viruses. TABULAR DATA, SEE
       ABSTRACT VOLUME. Biological data mainly revealed hepatic failure and
       severe lactate acidosis. Histological examination of liver biopsies
       showed diffuse microvesicular steatosis without necrosis, fibrosis or
       inflammation. DISCUSSION AND CONCLUSIONS: The only comparable case
       previously reported (Lai et al, 1991) showed close similarities in
       clinical, biological and histological manifestations with either lactate
       acidosis and microvesicular steatosis. We suggest that ddI may be
       responsible for fulminant hepatitis in AIDS patients. This toxic effect
       may be added to the potential adverse events occurring during ddI
       therapy.
 DE    Case Report  Didanosine/*ADVERSE EFFECTS  Hepatitis, Toxic/*ETIOLOGY
       Human  HIV Infections/DRUG THERAPY  HIV-1  Retrospective Studies
       MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).